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sevier Taiwan LLC. Open access under CSummary Gastrointestinal stromal tumors are nonepithelial neoplasms of the gastrointes-
tinal tract and have been increasingly recognized in recent years. In contrast, stromal tumor
outside the gastrointestinal tract is not frequently found. Here, we present a 57-year-old male
patient who had abdominal fullness for several months. It was caused by a 23-cm heteroge-
neous tumor mass that was successfully removed from the left upper abdominal cavity. The
tumor adhered tightly to adjacent organs but postoperative histopathological analysis revealed
no direct connection to the stomach, liver, pancreas, spleen, or kidneys. Immunohistochemical
examination of the tumor revealed proliferative spindle-shaped cells stained positive for
CD117 and CD34 and negative for smooth muscle actin and S-100. The patient received regular
follow up. A suspected recurrent liver metastatic lesion was noted 2 years later and radiofre-
quency ablation of the liver tumor was performed followed by oral imatinib treatment. No tu-
mor recurrence was detected at 3 years after radiofrequency ablation. This case reminds us
that extragastrointestinal stromal tumors should be considered in the differential diagnosis
when a large heterogeneous mass is present in the abdominal cavity. The characteristics of ex-
tragastrointestinal stromal tumor are described and the literature is reviewed in this report.
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Stromal tumor in abdominal cavity 137IntroductionGastrointestinal stromal tumor (GIST) is a nonepithelial
tumor in the digestive tract. The diagnosis and treatment of
gastrointestinal stromal tumors have increased in recent
years with the help of advanced immunohistochemical
methods. However, stromal tumors developing outside the
gastrointestinal tract, termed extragastrointestinal stromal
tumor (EGIST), are rarer than GIST. Here, we report a pa-
tient with a large tumor that grew outside the gastroin-
testinal tract in the abdominal cavity, with features of
stromal cells. It was diagnosed as EGIST. The characteristics
of this EGIST are described and the literature is reviewed
and discussed.
Case report
A 57-year-old man had a history of essential hypertension,
type 2 diabetic mellitus, and chronic constipation for
several years. He experienced epigastric discomfort in
2006. The sensation of the epigastric discomfort was dull
and compressive, and lasted approximately 30 minutes. At
that time, there was no dysphagia, odynophagia, nausea,
vomiting, heartburn, hunger pain, acid regurgitation, or
easy satiety. There was no overt precipitating, aggravating,
or alleviating factor. He took some antacids, and rapid
improvement was seen initially. However, after intermit-
tent treatment for 9 months, the same symptoms recurred
and became worse despite continued treatment. Occa-
sionally epigastric cramps and fullness followed. His appe-
tite was fair, but easy satiety and body weight loss ofw5 kg
were found. A fecal occult blood test was negative in two
separate studies.
On admission, a physical examination found that the
abdomen was flat without tenderness or rebounding pain
but there was a palpable soft tissue mass over the epigas-
tric region. The patient did not notice the epigastric mass
at all. Plain abdominal film showed an increased soft tissue
density over the upper abdomen (Fig. 1A). Whole abdom-
inal sonography disclosed that it was a cyst-like lesion, with
some bloodemucous like material inside. It was >20 cm in
diameter (Fig. 1B). Upper gastrointestinal endoscopyFigure 1 (A) Kidney, Ureter, Bladder (KUB) X ray found increase
displacement of transverse colon gas; (B) sonographic finding of tran
septation andmucous-like content in the epigastric and left upper qu
by the tumor at the head and body; (C) computed tomography showe
density at the central region and peripheral enhancement. The spleshowed an external compression sign over the posterior
wall of the gastric body with normal gastric mucosa.
Computed tomography of the upper abdomen revealed that
there was a large mass of heterogeneous density, measuring
23 cm  13 cm  20 cm, with possible central necrosis and
peripheral enhancement, and the spleen and stomach were
compressed by the mass (Fig. 1C). The patient soon
received surgical intervention. Because the tumor was
involved extensively, total gastrectomy, Roux-en-Y esoph-
agojejunostomy, splenectomy, distal subtotal pancreatec-
tomy, cholecystectomy, and segmental colectomy with
anastomosis were performed smoothly (Figs. 2A and 2B).
Grossly, there was no connecting stalk between the
tumor and adjacent organs. Serial microscopic surveys
showed that the stomach, pancreas, and spleen were
compressed by the stromal cell tumor. There was fibrosis of
the adjacent pancreatic tissue. There was no lymph node
metastasis. The microscopic study of the tumor part
showed spindle-shaped neoplastic cells with uniform and
syncytial-appearing eosinophilic cytoplasm (Fig. 3A). The
mitotic count was 12/50 high-power field (HPF). The MIB-1
test showed an increased proliferation index > 10%.
Immunohistochemical study of the tumor cells showed
positive for CD117 and CD34, and negative for smooth
muscle actin and S-100 (Fig. 3B).
The postoperative course was smooth and uneventful.
Two years later, abdominal computed tomography showed
a metastatic nodule in the lateral segment of the liver.
Radiofrequency ablation of the tumor was performed, fol-
lowed by oral imatinib treatment. The patient remained
free from tumor recurrence in the subsequent 3 years and is
still under follow up.Discussion
GIST constitutes only 1% of the total primary digestive tract
cancer. The annual incidence of GIST is 15e20 cases per
million population [1e4]. Due to the improvement of
diagnostic immunohistochemical techniques, the numbers
of GISTs have increased in recent years. GIST occurs in and
throughout the whole gastrointestinal tract. The most
common sites of origin are the stomach (60%), followed byd soft tissue density over the epigastric region with downward
sverse and longitudinal view. There was a large cystic lesion with
adrant of the abdomen. Thepancreaswas compressed downward
d a large mass, approximately 23 cm  13 cm 20 cm, with low
en and stomach were heavily compressed by the tumor mass.
Figure 2 (A) The tumor was seen beneath the colon and omentum when the abdominal cavity was opened; (B) surgical specimen
showing the resected portion of the stomach (arrow) and spleen (dot arrow). The ruler is 15 cm in length.
138 C.-K. Chou et al.jejunum and ileum (30%), duodenum (5%), and colorectum
(<5%). Only a small number of cases (<1%) have been re-
ported in the esophagus and appendix. By contrast, EGISTs
are relatively rarer compared with GISTs.
The cellular origin of GIST is presumed to be the inter-
stitial cells of Cajal, while the origins of EGIST remain
inconclusive. Interstitial cells of Cajal are pacemaker cells
present throughout the wall of the gastrointestinal tract to
regulate motility. They express CD117 antigen, which is the
c-Kit receptor tyrosine kinase. Approximately 95% of GISTs
are positive for CD117 [5e7]. However, primary stromal
cells developed in nongastrointestinal tract tissues are
possible. Recently, the existence of interstitial cells of
Cajal in the exocrine pancreas has been discovered and
reported to have a phenotype similar to that of enteric
Cajal cells [8,9]. There are several reports of cases of pri-
mary stromal tumors originating in the pancreas [10e12],
urinary bladder [13], prostate [14], and scrotum [15].
Moreover, one case report showed that a cirrhotic patient
developed a subcutaneous EGIST nodule in the perineum
after liver transplantation [16]. More recently, a primary
intrathoracic EGIST arising in the pleura has been reported
[17]. It was unusual in our case that this EGIST grew in the
abdominal cavity and showed no histological evidence of
any connection to the adjacent organs. Besides, there was
no other GIST detected in this patient. Thus, it could be a
primary EGIST that had developed from the peritoneum or
other tissues in the abdominal cavity. Although it has been
proposed that EGISTs could be due to metastasis or simply
GISTs detached from the primary origin [2,18,19], theFigure 3 (A) The tumor specimen appeared spindle-shaped and
immunohistochemical study showed positive CD117 staining; smooclinical and histological evidence of our case appears to be
against the above possibilities.
There are no specific clinical characteristics of EGIST
within the abdominal cavity. The common clinical pre-
sentations of GIST such as gastrointestinal tract bleeding
and obstruction are usually absent in EGIST. EGIST lacks
mucosal involvement, therefore, intraabdominal EGIST is
often asymptomatic and may grow to a relatively large size
when it is initially diagnosed. Bai et al [20] presented one
retrospective study of 30 cases of intraabdominal EGIST
with a median size of 12.5 cm. Kobayashi et al [21] have
reported one giant EGIST 18 cm in size. In our case report,
the tumor had grown to >20 cm.
There are several parameters to evaluate the prognosis
of GIST. In a retrospective analysis, Langer et al [22] found
that tumor size > 5 cm, mitotic count > 2/HPF, and pro-
liferation index > 10% were markedly associated with a
shorter recurrence-free survival rate. As for EGIST, Yama-
moto et al [18] reviewed 39 cases and concluded that tu-
mors with high mitotic counts ( 5/50 HPF), or a high Ki-67
labeling index ( 10%), were significantly correlated with
worse prognosis. In our case, the mitotic count was 12/50
HPF. Overall, the tumor size, mitotic count, and prolifera-
tion index were compatible with the high-risk criteria of the
previous study.
Currently, surgery and imatinib are two powerful
methods for treatment of GIST. For primary resectable
GIST, only complete surgical resection offers a possibility of
cure. The main goal of surgery is to remove the tumor with
negative margins. A 2-cm margin should be sought. Regionalarranged in a bundle (hematoxylin and eosin stain, 400); (B)
th muscle stain was negative.
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rarely (<5%) metastasizes to lymph nodes [23]. The tyrosine
kinase inhibitors (TKIs) such as imatinib and sunitinib are
used primarily for metastatic, recurrent, and unresectable
GIST. The phase III trial ACOSOG Z9001 demonstrated that
imatinib can be considered as GIST patients recover from
surgical procedures, especially in those with a significant
risk of recurrence (tumor size > 10 cm, >5 mitoses/50 HPF,
rupture, intraperitoneal hemorrhage, and multifocal GIST).
However, the impact of this approach on long-term survival
remains unclear [23]. In our case, TKI was prescribed after
the metastatic lesion developed and it appeared to be
beneficial and effective in tumor control.
In summary, we report here the case of a man with a 20-
cm EGIST in the abdominal cavity who received resection,
initially, then Radiofrequency ablation formetastasis. Under
TKI treatment, the patient remained recurrence free for 3
years. An EGIST of large size and high mitotic rate should be
followed up closely. Local ablation combined with TKI may
be used to control tumor metastasis and recurrence.
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